Professor John Reilly BSc, MD, FRCP, FRCPATH

Consultant Heamatologist

Address
H Floor
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF

Tel: +44(0)114 2711730
Fax: +44(0)114 2711733
Email: j.t.reilly@sheffield.ac.uk

Name of Secretary: Julie West
Secretary Telephone: +44 (0)114 2711732

Career History

Professor Reilly was appointed consultant haematologist in Sheffield in 1988, with a specialist interest in the area of haemato-oncology. Before this he was a research fellow in Liverpool where he studied the pathogenesis of bone marrow stromal protein hyperplasia that characterises the chronic myeloproliferative disorders. He is currently Director of the United Kingdom National External Quality Assurance Scheme for Leucocyte Immunophenotyping (UKNEQAS).

Research Interests

Professor Reilly´s current research interests are the pathogenesis and treatment of both chronic and acute myeloid malignancies. He is past editor of the British Journal of Haematology and a founder member of the International Working Group for Myelofibrosis treatment and Research (IWG-MRT) and the UK Chronic Myeloproliferative Disorders Group. He is also director of UKNEQAS for leukaemia immunophenotypng and haemato-oncology molecular diagnosis.

He is the author of over 130 scientific publications and is frequently an invited speaker at national and international meetings.

Principle Funding Sources

Leukaemia Research Fund
Leukaemia and Myeloma Fund (CSUH)

Members of Research Group

Dr Anne Goodeve (Reader)
Dr Peter Winship (Lecturer)
Mr D Gilby (PhD Student)

Representative Publications

Care, R.S., Valk, P.J.M., Goodeve, A.C., Abu-Duhier, F., Geertsma-Kleinekoort, W.M.C., Wilson, G.A., Gari, M.A., Peake, I. R., Löwenberg, B. and Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775-777.

Reilly, J.T. (2005) Pathogenesis of acute myeloid leukaemia and inv(16): a paradigm for understanding leukaemogenesis. British Journal of Haematology, 128, 18-34.

Harrison, C., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Welt, J.D., Reilly. J.T., Grigg, A.P., Revell, P., Woodcock, B.E., Green, A.R. (2005). A randomized comparison of hydroxyurea and anagrelide in high-risk essential thrombocythaemia: the Medcical Research Council PT-1 trial. New England Journal of Medicine, 353, 33-45.

McMullin, M.F., Bareford, D., Campbell, P., Green, A.R., arrison, C., Hunt, B., Oscier, D., Polkey, M., Reilly. J.T., Rosenthal, E., Ryan, K., Pearson, T.C. & Wilkins, B. (2005). Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 130, 174-195.

Barosi G, Bordessoule, D., Briere, J., Cervantes, F., Demory, J-L., Dupriez, B., Gisslinger, H., Griesshammer, M., Hasselbalch, H., Kusec, R., Le Bousse-Kerdiles, M-C., Liberato, N.L., Marchetti, M., Reilly, J.T. & Thiele, J. (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myeofibrosis Network (EUMNET). Blood, 106, 2849-2853.).

Campbell, P.J., Griesshammer, M., Dohner, K., Dohmer, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdiels, M-C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J-J, Viallard, J-F., Briere, J., Harrison, C.N., Green, A.J.& Reilly, J.T. (2005) The V617F mutation in JAK-2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 2098-2100.

Campbell, P, J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M., Erber, W.N., Bareford, D., Wilkins, B., Reilly, J.T., Milligan, D.W., Smith, S.R., Harrison, C. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945-1953.

Campbell, P.J., Baxter E. J., Beer, P.A., Scott, L., Bench, A.J., Kusec, R., Hasselbalch, H.C., Giraudier, S., Le Bousse-Kerdiels, M-C., Griesshammer, M., Reilly, J.T., Harrison, C.N., Green, A.R. (2006) Timing of JAK2 V617F mutation in MPDs and role of co-operating mutations: clonality, cytogenetics and leukaemia transformation. Blood, 108, 3548-3555.

Tefferi A, Barosi G, Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R, T., Oenike, O., Cortes, J., Wadleigh, M., Solberg, L.A., Camoriano, J.K., Gisslinger H, Noel, P., thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C.P., Gilliland, D.G. & Kantarjian, H. (2006) International Working Group (IWG) Concensus Criteria for treatment response in myelofibrosis with myeloid metaplasia: on behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). Blood, 108, 1497-1503.

Tefferi A, Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: from an ad hoc international expert panel. Blood, in press.